PEYRONIE´S DISEASE

Czech version

Authors: Aleš Horák
Authors‘ workplace: ANDROPHARM medical, s. r. o., Ostrava
Published in: Ces Urol 2017; 21(1): 43-58
Category: Review article

Overview

Peyronie‘s disease (PD) is a chronic non‑fatal disease characterized by the occurrence of penile fibrous plaques in the tunica albuginea (TA). Clinical symptoms are pain, palpable induration, or penile deformity of the penis. Sometimes it may be present with erectile dysfunction associated with patient‘s mental deterioration. The most commonly affected are males between 40–60 years of age. The causes of PD are not entirely clear, probably multifactorial. Therapy is problematic. Therapeutic options are conservative and surgical.

KEY WORDS:
Peyronie‘s disease, fibrous plaque, curvature, deformity, conservative treatment, surgical treatment, penile prosthesis

Sources

1. Ralph DJ, Pryor JP. Peyronie’s disease. In: Carson CC, Kirby RS, Goldstein I. (ed.). Textbook of erectie dysfunction. Isis Medical Media, Oxford, 1999: 515–527. ISBN: 899066‑96‑9

2. Garaffa G, Trost LW, Serefoglu EC, Ralph D, Hellstrom WJG. Understanding the course of Peyronie’s disease. Int J Clin Pract. 2013; 67(8): 781–788.

3. Shamloul R; Bella AJ. Management of Peyronie’s disease in the aging male, aging health. 2011; 7(1): 6578. Dostupný také z: www.medscape.com/viewarticle/740710_print

4. Smith JF, Walsh TJ, Lue TF. Peyronie’s disease: a critical appraisal of current. Diagnosis and treatment. Int J Impot Res. 2008; 20(5): 445–459.

5. Hatzimouratidis K, Eardley I, Giuliano F, Moncada I, Salonia A. Guidelines on penile curvature. Eur Urol 2012 Sep; 62(3): 543–552.

6. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001; 88: 727.

7. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie’s disease in men over 50yold from Southern Brazil. Int J Impot Res 2001; 13: 291.

8. Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171: 2350.

9. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester. Minnesota, 1950 through 1984. J Urol 1991; 146: 1007.

10. Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O, Ozsoy C. Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. Int J Impot Res 2004; 16: 540.

11. Kendirci M, Trost L, Sikka SC, Hellstrom WJ. Diabetes mellitus is associated with severe Peyronie’s disease. BJU Int 2007; 99: 383.

12. Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie’s disease. Drugs 2007; 67: 527.

13. Barrett Harlow B, Wang R. Oral therapy for Peyronie’s disease, does it work? Transl Androl Urol. 2016; 5(3): 296–302.

14. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie’s disease. A pilot study. Urology, 44, 1994; 2: 291–295.

15. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized doubleblind, placebo controlled study. Int J Impot Res 2004; 16: 238.

16. Teloken C, Rhoden EL, Grazziotin TM, Da Ros CT, Sogari PR, Souto CAV. Tamoxifenversus placebo in the treatment of Peyronie’s disease, J. Urol., 162, 1999; 15: 2003–2005.

17. Ralph DJ, Brooks GF, Pryor JP. The treatment of Peyronie’s disease with tamoxifen. Brit. J. Urol., 70, 19 92; 648 .

18. Biagiotti G, Cavallini G. Acetyl Lcarnitine vs. tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001; 88: 63.

19. Wagenknecht LV. Differential therapies in various stages of penile induration. Arch Esp Urol 1996; 49: 285.

20. Kladenský J, Pacík D, Čermák A. Potaba – Glenwood – unsere Erfahrungen mit derkonservativen Behandlung der Induratio penis plastica. Uroscop., 1993; 9: 29.

21. Carson CC. Potassium paraaminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol 1997; 3: 135.

22. Bremer J. Carnitine‑metabolism and functions. Physiol Rev 1983; 63: 1420.

23. Karlic H, Lohninger A. Supplementation of Lcarnitinein athletes: does it make sense? Nutrition 2004; 20: 709 s.

24. Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3: 111.

25. Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie’s disease. Br J Urol 1978; 50: 111.

26. Vrabec J, Mathernová V. Kalciové blokátory v liečbě induratio penis plastica. Slovenský lekár, 1997; 7: 21–23.

27. Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J. Urol., 158, 1997; 10: 1395 –139 9.

28. Levine LA, Merrick PL, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J. Urol., 151, 1994; 6: 1522–1524.

29. Hellstrom WJ, Kendirci M, Matern R, et al. Singleblind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha2B for minimally invasive treatment for Peyronie’s disease. J Urol 2006; 176: 394.

30. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, singlecenter, nonplacebo controlled study. J Sex Med 2008; 5: 180.

31. De Sanctis PN, Furey CA Jr. Steroid injection for Peyronie’s disease: A 10‑year summary and review of 38 cases, J. Urol., 97, 1967; 114.

32. Carson CCIII, Coughlin PWF. Radiation therapy for Peyronie’s disease: is there a place?, J. Urol., 134, 1985; 684 .

33 Mulhall JP, Hall M, Broderick G A, Incrocci L. Radiation therapy in Peyronie’s disease J Sex Med.2012 May; 9(5): 1435–1441.

34. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a doubleblind, placebo controlled trial. J Urol 2007; 177: 972.

35. Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multidrug administration for Peyronie’s disease: preliminary results. J Androl 2000; 21: 85.

36. Knobloch K, Kuehn M, Vogt PM. Focused extracorporeal shockwave therapy in Dupuytren’s disease hypothesis. Med Hypotheses. 2011 May; 76(5): 6357.

37. Butz M, Teichert HM, Fuerth D. Treatment of Peyronie’s disease by extracorporal shockwawes. J. Urol., 1999; 159: 118.

38. Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebocontrolled, prospective, randomized, singleblind study. J Sex Med. 2013 Nov; 10(11): 2815–2821.

39. Abdel Salam Y, Budair Z, Renner C, et al. Treatment of Peyronie’s disease by extracorporeal shockwave therapy: evaluation of our preliminary results. J Endourol 1999; 13: 549.

40. Drlík P, Kočárek J. Sedmileté zkušenosti s aplikací rázových vln u mužů s induratio penis plastica (IPP). Ces Urol 2015; 19(4): 296–303.

41. Drlík P, Loško J, Křístek V, Kőhler O. Matematické modelování deformace penisu při induratio penis plastica po terapii rázovými vlnami (swt). Ces Urol, 2012; 16(1): 37–42.

42. Martínez Salamanca JI, Egui A, Moncada I, et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014 Feb; 11(2): 506–515.

43. Yafi FA, Pinsky MR, Stewart C, et al. The effect of duration of penile traction therapy in patients under-going intralesional injection therapy for Peyronie’s disease. J Urol. 2015 Sep; 194(3): 754–758.

44. Gur S, Kadowitz PJ, Hellstrom WJ. Drugs of the future for Peyronie’s disease. Med Hypotheses; 2012 Feb; 78(2): 305–311.

45. Nesbit RM. Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 1965; 93: 230.

46. Gholami SS, Lue TF. Correction of penile curvature using the 16dot plication technique: a review of 132 patients. J Urol, 2002; 167: 2066.

47. Montorsi F, Salonia A, Maga T, et al. Evidence based assessment of longterm results of plaque incision and vein grafting for Peyronie’s disease. J Urol 2000; 163: 1704.

48. Hellstrom WJ, Usta MF. Surgical approaches for advanced Peyronie’s disease patients. Int J Impot Res 2003; 15(Suppl 5): S121.

49. Mulcahy JJ, Wilson SK. Management of Peyronie’s disease with penile prostheses. Int J Impot Res 2002; 14: 384.

50. Wilson SK, Delk II JR. A new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol 1994; 152: 1121.

51. Akin Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med 2006; 3: 743.

52. Wilson SK, Delk II JR, Salem E. Longterm survival of inflatable penile prostheses: single surgical group experience with 2 384 first time implants spanning two decades. J Sex Med 2007; 4: 1074.

53. Carson CC. Penile prosthesis implantation in the treatment of Peyronie’s disease and erectile dysfunction. Int J Impot Res 2000; 12(Suppl 4): 122. 54. Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie’s disease: a critical analysis. European Urology 2006; 50: 235–248.